This webcast features: Paul Jorjorian, Director, Global Technology Transfer, Patheon Biopharmaceutical companies are facing increasing constraints when developing and manufacturing their large molecule drugs. Development labs and manufacturing suites have limited capacity making it nearly impossible to right size internally for uncertain forecasts. As a result, selection of the right biomanufacturing partner has never been more important – for small and mid-size biopharma companies alike. There are an ever-increasing number of options and many criteria to consider during the vendor…